TranSINETM Therapeutics, is a new, rapidly evolving biotech based in the research hub of Cambridge, UK, that is focused on the development of SINEUPsTM, a revolutionary platform technology that specifically increases the translation of target proteins in a fully plug-and-play manner. This unique and scalable platform enables TranSINETM to address unmet medical needs and build differentiated products that cannot be generated with other technologies.
TranSINETM Therapeutics has world class founders, Professor Stefano Gustincich and Professor Piero Carninci, pioneers in the fields of functional genomics and transcriptomics. The identification of SINEUPsTM, a novel class of long non-coding RNAs, was first reported in Carrieri et al., Nature. 2012;491(7424):454-457. In 2020, the value of this ground-breaking new therapeutic class was realized when TranSINETM Therapeutics received significant seed funding from Takeda Ventures Inc. and the Dementia Discovery Fund to build a pipeline of novel therapeutics across multiple disease areas including ophthalmology and neurology.
TranSINETM Therapeutics is evolving fast. With the development of the TranSINETM Therapeutics Labs at the Babraham Research Campus, we are currently recruiting for: